TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02933866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS topical
Description: topical treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical
Description: topical treatment
Study: NCT00696449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: All Subjects will treat the face once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: All Subjects will treat the face once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: All Subjects will treat the face once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: All Subjects will treat the face once daily in the evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: frequent visits
Description: This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic reminder
Description: This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent reminder
Description: In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.
Study: NCT02474264

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial function assessment
Description: reactive hyperemia index

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial function assessment
Description: reactive hyperemia index

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular biomarkers
Description: Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular biomarkers
Description: Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial cells
Description: Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial cells
Description: Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
Study: NCT03834805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung and liver elastography measurement of fetus
Description: Other: lung and liver elastography measurement of fetus
Study: NCT02439008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples collection before radiotherapy
Description: Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~* Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples collection during radiotherapy
Description: * Sample T1: within 15 minutes after the administration of the first fraction,~* Sample T2: within 15 minutes after the administration of the second fraction,~* Sample T3: within 15 minutes after the administration of the third fraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples collection after radiotherapy
Description: * Sample T4: one week after the end of the radiotherapy,~* Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT01345032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Description: Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone consultation
Description: Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
Study: NCT03772483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with conventional syringe
Description: Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with conventional syringe + VR device
Description: Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL
Study: NCT02101632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bee Venom Ointment
Description: 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline Ointment
Description: 2 weeks
Study: NCT02789033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan
Description: Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan
Description: Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide dinitrate
Description: Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide dinitrate
Description: Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03423888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal cannula oxygen therapy (HNFC)
Description: Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC.
Study: NCT03294863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace Scar Therapy Device
Description: 16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Without the embrace Scar Therapy Device
Study: NCT04842058

Intervention type: OTHER
Intervention: Mobilisation procedure
Description: A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.

Intervention type: OTHER
Intervention: Mobilisation procedure
Description: A standardized mobilization procedure was performed preoperatively \~ 1h before surgery and was repeated 6h and 24h after surgery. The mobilization procedure included patient supine rest (5 minutes), followed by 45° passive leg raise (PLR) (3 minutes), supine rest (5 minutes), sitting on the edge of the bed with feet resting on the floor (3 minutes) followed by standing using a walker while the patient was encouraged verbally to stand on toes and shift body weight from one leg to the other (3 minutes) and finally rest in supine position (5 minutes). The procedure was terminated prematurely in any position if patients experienced unbearable symptoms of OI or upon a decrease of systolic arterial pressure (SAP) \> 30 mmHg.
Study: NCT00241917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hepatitis C educational video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: Prevention education video about hepatitis C
Study: NCT00508560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reward
Description: Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
Study: NCT04809246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'One-stop-shop' hepatitis clinic
Description: Establishment of a 'one-stop-shop' hepatitis clinic, integrating point-of-care HCV RNA testing, followed by clinical assessment, non-invasive liver fibrosis assessment by fibro-elastography (Fibroscan), and early DAA prescription (for those with chronic HCV) followed by linkage to ongoing hepatitis care, all in the same 60-minute visit.
Study: NCT03197064

Intervention type: DRUG
Group type: OTHER
Intervention: Fosaprepitant 150 mg
Description: Antiemetic used to prevent nausea and vomiting after general anesthesia.
Study: NCT03366909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based relapse prevention (MBRP)
Description: These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: classic therapy
Description: These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
Study: NCT03820921

Intervention type: DIAGNOSTIC_TEST
Intervention: EUS-FNB
Description: EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA).

Intervention type: OTHER
Intervention: Immunohistochemistry
Description: IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
Study: NCT00133406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glycine
Description: 0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: 40 mg twice weekly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: 40 mg twice weekly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zinc
Description: 40 mg twice weekly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: 40 mg twice weekly for 12 months
Study: NCT01340677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 50 mg
Description: Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
Study: NCT02818725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: PANITUMUMAB: 6 mg/kg on day 2
Study: NCT01064661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single probiotic arm of L-NCFM alone
Description: Single probiotic of L-NCFM alone pills BID (2x10\^10 cfu total bacteria per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blend probiotic arm of L-NCFM and B-LBi07
Description: Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10\^10 cfu total bacteria per day)
Study: NCT02571153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Description: Intravenous ketamine 0.4 mg/kg after induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous normal saline 0.9% 5 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Description: Intravenous ketamine 0.2 mg/kg after induction of anesthesia
Study: NCT01034605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PinnoThin
Description: 6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
Study: NCT02090036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine (For artemether-lumefantrine+primaquine arm)
Description: A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (For artemether-lumefantrine arm)
Description: Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
Study: NCT01856868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (-)-epicatechin
Description: purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
Study: NCT01587144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucanthone
Description: Lucanthone will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the common terminology criteria (CTC) nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 60 Gy administered in 30 fractions for 42 days in the concomitant phase.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: 60 Gy administered in 30 fractions for 42 days in the concomitant phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks during the concomitant phase. In the maintenance phase, placebo will be administered on days 1-5 of a 28-day cycle for 6 cycles.
Study: NCT00931034

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: South Beach Diet with South Beach Diet Products

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association Diabetes Meal Plan
Study: NCT01523418

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
Study: NCT00462306

Intervention type: PROCEDURE
Intervention: Survey: Berlin questionnaire
Description: Completion of questionnaire

Intervention type: PROCEDURE
Intervention: Survey: Berlin questionnaire
Description: Completion of questionnaire
Study: NCT01329627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/doxorubicin/cyclophosphamide
Description: Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/doxorubicin/cyclophosphamide
Description: Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.